{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bing C"],"funding":["the Fundamental Research Funds for the Central Universities","the Innovative Experiment Projects of Educational Ministry of China for Undergraduate"],"pagination":["771-782"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11290751"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(9)"],"pubmed_abstract":["<b>Aim:</b> The response of <i>E. coli</i> ATCC8739 to Brevinin-2CE (B2CE) was evaluated as a strategy to prevent the development of antimicrobial peptide (AMP)-resistant bacteria. <b>Methods:</b> Gene expression levels were detected by transcriptome sequencing and RT-PCR. Target genes were knocked out using CRISPR-Cas9. MIC was measured to evaluate strain resistance. <b>Results:</b> Expression of <i>acrZ</i> and <i>sugE</i> were increased with B2CE stimulation. ATCC8739Δ<i>acrZ</i> and ATCC8739Δ<i>sugE</i> showed twofold and fourfold increased sensitivity, respectively. The survival rate of ATCC8739 was reduced in the presence of B2CE/chlorpromazine (CPZ). Combinations of other AMPs with CPZ also showed antibacterial effects. <b>Conclusion:</b> The results indicate that combinations of AMPs/efflux pump inhibitors (EPIs) may be a potential approach to combat resistant bacteria."],"journal":["Future microbiology"],"pubmed_title":["Efflux pump inhibitor chlorpromazine effectively increases the susceptibility of <i>Escherichia coli</i> to antimicrobial peptide Brevinin-2CE."],"pmcid":["PMC11290751"],"funding_grant_id":["GK202302003","S202310718118"],"pubmed_authors":["Mengjuan A","Zhi L","Chixin Z","Bing C","Yan S","Xinyu M","Xinyao T"],"additional_accession":[]},"is_claimable":false,"name":"Efflux pump inhibitor chlorpromazine effectively increases the susceptibility of <i>Escherichia coli</i> to antimicrobial peptide Brevinin-2CE.","description":"<b>Aim:</b> The response of <i>E. coli</i> ATCC8739 to Brevinin-2CE (B2CE) was evaluated as a strategy to prevent the development of antimicrobial peptide (AMP)-resistant bacteria. <b>Methods:</b> Gene expression levels were detected by transcriptome sequencing and RT-PCR. Target genes were knocked out using CRISPR-Cas9. MIC was measured to evaluate strain resistance. <b>Results:</b> Expression of <i>acrZ</i> and <i>sugE</i> were increased with B2CE stimulation. ATCC8739Δ<i>acrZ</i> and ATCC8739Δ<i>sugE</i> showed twofold and fourfold increased sensitivity, respectively. The survival rate of ATCC8739 was reduced in the presence of B2CE/chlorpromazine (CPZ). Combinations of other AMPs with CPZ also showed antibacterial effects. <b>Conclusion:</b> The results indicate that combinations of AMPs/efflux pump inhibitors (EPIs) may be a potential approach to combat resistant bacteria.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2025-06-27T03:05:33.239Z","creation":"2025-06-27T03:05:33.239Z"},"accession":"S-EPMC11290751","cross_references":{"pubmed":["38683168"],"doi":["10.2217/fmb-2023-0272"]}}